|
(Health-NewsWire.Net, April 22, 2015 ) Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information.
Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=310177 . (This is a premium report Price at US$2000 for a single user License)
This report provides comprehensive information on the therapeutic development for Cholera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Inquire for discount at http://www.rnrmarketresearch.com/contacts/discount?rname=310177 .
Scope:
• Coverage of the Cholera pipeline on the basis of target, MoA, route of administration and molecule type
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews key players involved in the therapeutics development for Cholera and enlists all their major and minor projects
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
Reasons to Buy:
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify and understand important and diverse types of therapeutics under development for Cholera
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Explore more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
Table of Contents:
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cholera Overview 6
Therapeutics Development 7
Pipeline Products for Cholera - Overview 7
Pipeline Products for Cholera - Comparative Analysis 8
Cholera - Therapeutics under Development by Companies 9
Cholera - Therapeutics under Investigation by Universities/Institutes 10
RnR Market Research
Ritesh Tiwari
+ 1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com 
|
